Global Alpha Emitters Market

Alpha Emitters Comprehensive Study by Application (Pancreatic Cancer, Prostate Cancer, Ovarian Cancer, Other), Radionuclide Type (Fermium, Astatine, Curium, Radium, Actinium, Radon, Bismuth, Other), End-User (Hospitals, Medical Research Institutions, Others) Players and Region - Global Market Outlook to 2028

Alpha Emitters Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Alpha Emitters Market Scope
Alpha emitters are crucial in the therapy of cancer. The properties of alpha emitters have resulted in significant distinctions between this field and other nuclear medicine fields. Alpha particles have been widely used in medical studies due to their limited range and high LET (deposit energy per unit length of passage). For example, the International Agency for Research on Cancer (IARC) expected that by 2040, the global burden of cancer will have increased to 27.5 million active cancer occurrences and 16.3 million cancer deaths, owing to population growth and aging. Cancer kills over 70% of people in low- and middle-income countries.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBayer AG (Germany), IBA Radiopharma Solution (Belgium), Alpha Tau Medical Ltd (Israel), Actinium Pharmaceutical Inc. (United States), RadioMedix Inc. (United States), Fusion Pharmaceuticals (Canada) and Telix Pharmaceuticals (Australia)
CAGR%


The market for alpha emitters is less competitive, with only a few big players. Market leaders include IBA Radiopharma Solutions, Bayer AG, Alpha Tau Medical Ltd, Actinium Pharmaceutical Inc., Telix Pharmaceuticals Ltd, RadioMedix Inc., and Fusion Pharmaceuticals. Mergers and acquisitions, expansions, investments, new service launches, and collaborations are some of the companies' preferred market-exploration strategies.

Bayer AG (Germany), IBA Radiopharma Solution (Belgium), Alpha Tau Medical Ltd (Israel), Actinium Pharmaceutical Inc. (United States), RadioMedix Inc. (United States), Fusion Pharmaceuticals (Canada) and Telix Pharmaceuticals (Australia) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Alpha Emitters market by Type , by Application (Pancreatic Cancer, Prostate Cancer, Ovarian Cancer and Other) and Region with country level break-up.

On the basis of geography, the market of Alpha Emitters has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In July 2021, Alpha Tau Medical Limited and Healthcare Capital Corp have signed a formal business combination agreement. This transaction will be used to fund Alpha Tau's clinical plan, which includes gaining FDA marketing authorization, doing extensive R&D, expanding manufacturing capacity, and preparing for commercialization.
In Nov 2021, RadioMedix has awarded AlphaMedix, a novel alpha-emitter-tagged peptide for the treatment of somatostatin receptor-positive neuroendocrine tumors, a USD 2 million grant to support Phase I/II clinical research.
In June 2022, US Food and Drug Administration approved innovative alpha-radiation cancer therapy Alpha DaRT of Alpha Tau Medical Ltd. this involve the Company's Investigational Device Exemption (IDE) application to initiate its multi-center pivotal study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC) using the Alpha DaRT

Influencing Trend:
Medical Application in Ovarian Cancer has high Demand in Market

Market Growth Drivers:
Increasing Incidence and Disorder of Target Conditions and Innovating Advanced Technology in the Market

Challenges:
High Equipment Costs and Stringent Government Rules and Regulations for New Product Approvals

Restraints:
The High Cost Required For Research & Development Activity

Opportunities:
Use of Radiopharmaceuticals in Neurological Applications and Increasing Investment and Funding For Adopting Strong Technique

Key Target Audience
Industry Association, Downstream Vendors, Alpha Emitters Manufactures, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Investors

Report Objectives / Segmentation Covered

By Application
  • Pancreatic Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Other
By Radionuclide Type
  • Fermium
  • Astatine
  • Curium
  • Radium
  • Actinium
  • Radon
  • Bismuth
  • Other

By End-User
  • Hospitals
  • Medical Research Institutions
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence and Disorder of Target Conditions
      • 3.2.2. Innovating Advanced Technology in the Market
    • 3.3. Market Challenges
      • 3.3.1. High Equipment Costs
      • 3.3.2. Stringent Government Rules and Regulations for New Product Approvals
    • 3.4. Market Trends
      • 3.4.1. Medical Application in Ovarian Cancer has high Demand in Market
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Alpha Emitters, by Application, Radionuclide Type, End-User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Alpha Emitters (Value)
      • 5.2.1. Global Alpha Emitters by: Application (Value)
        • 5.2.1.1. Pancreatic Cancer
        • 5.2.1.2. Prostate Cancer
        • 5.2.1.3. Ovarian Cancer
        • 5.2.1.4. Other
      • 5.2.2. Global Alpha Emitters by: Radionuclide Type (Value)
        • 5.2.2.1. Fermium
        • 5.2.2.2. Astatine
        • 5.2.2.3. Curium
        • 5.2.2.4. Radium
        • 5.2.2.5. Actinium
        • 5.2.2.6. Radon
        • 5.2.2.7. Bismuth
        • 5.2.2.8. Other
      • 5.2.3. Global Alpha Emitters by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Medical Research Institutions
        • 5.2.3.3. Others
      • 5.2.4. Global Alpha Emitters Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Alpha Emitters (Price)
  • 6. Alpha Emitters: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. IBA Radiopharma Solution (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Alpha Tau Medical Ltd (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Actinium Pharmaceutical Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. RadioMedix Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fusion Pharmaceuticals (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Telix Pharmaceuticals (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Alpha Emitters Sale, by Application, Radionuclide Type, End-User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Alpha Emitters (Value)
      • 7.2.1. Global Alpha Emitters by: Application (Value)
        • 7.2.1.1. Pancreatic Cancer
        • 7.2.1.2. Prostate Cancer
        • 7.2.1.3. Ovarian Cancer
        • 7.2.1.4. Other
      • 7.2.2. Global Alpha Emitters by: Radionuclide Type (Value)
        • 7.2.2.1. Fermium
        • 7.2.2.2. Astatine
        • 7.2.2.3. Curium
        • 7.2.2.4. Radium
        • 7.2.2.5. Actinium
        • 7.2.2.6. Radon
        • 7.2.2.7. Bismuth
        • 7.2.2.8. Other
      • 7.2.3. Global Alpha Emitters by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Medical Research Institutions
        • 7.2.3.3. Others
      • 7.2.4. Global Alpha Emitters Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Alpha Emitters (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Alpha Emitters: by Application(USD Million)
  • Table 2. Alpha Emitters Pancreatic Cancer , by Region USD Million (2017-2022)
  • Table 3. Alpha Emitters Prostate Cancer , by Region USD Million (2017-2022)
  • Table 4. Alpha Emitters Ovarian Cancer , by Region USD Million (2017-2022)
  • Table 5. Alpha Emitters Other , by Region USD Million (2017-2022)
  • Table 6. Alpha Emitters: by Radionuclide Type(USD Million)
  • Table 7. Alpha Emitters Fermium , by Region USD Million (2017-2022)
  • Table 8. Alpha Emitters Astatine , by Region USD Million (2017-2022)
  • Table 9. Alpha Emitters Curium , by Region USD Million (2017-2022)
  • Table 10. Alpha Emitters Radium , by Region USD Million (2017-2022)
  • Table 11. Alpha Emitters Actinium , by Region USD Million (2017-2022)
  • Table 12. Alpha Emitters Radon , by Region USD Million (2017-2022)
  • Table 13. Alpha Emitters Bismuth , by Region USD Million (2017-2022)
  • Table 14. Alpha Emitters Other , by Region USD Million (2017-2022)
  • Table 15. Alpha Emitters: by End-User(USD Million)
  • Table 16. Alpha Emitters Hospitals , by Region USD Million (2017-2022)
  • Table 17. Alpha Emitters Medical Research Institutions , by Region USD Million (2017-2022)
  • Table 18. Alpha Emitters Others , by Region USD Million (2017-2022)
  • Table 19. South America Alpha Emitters, by Country USD Million (2017-2022)
  • Table 20. South America Alpha Emitters, by Application USD Million (2017-2022)
  • Table 21. South America Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 22. South America Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 23. Brazil Alpha Emitters, by Application USD Million (2017-2022)
  • Table 24. Brazil Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 25. Brazil Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 26. Argentina Alpha Emitters, by Application USD Million (2017-2022)
  • Table 27. Argentina Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 28. Argentina Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 29. Rest of South America Alpha Emitters, by Application USD Million (2017-2022)
  • Table 30. Rest of South America Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 31. Rest of South America Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 32. Asia Pacific Alpha Emitters, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Alpha Emitters, by Application USD Million (2017-2022)
  • Table 34. Asia Pacific Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 35. Asia Pacific Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 36. China Alpha Emitters, by Application USD Million (2017-2022)
  • Table 37. China Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 38. China Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 39. Japan Alpha Emitters, by Application USD Million (2017-2022)
  • Table 40. Japan Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 41. Japan Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 42. India Alpha Emitters, by Application USD Million (2017-2022)
  • Table 43. India Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 44. India Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 45. South Korea Alpha Emitters, by Application USD Million (2017-2022)
  • Table 46. South Korea Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 47. South Korea Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 48. Australia Alpha Emitters, by Application USD Million (2017-2022)
  • Table 49. Australia Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 50. Australia Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Alpha Emitters, by Application USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 54. Europe Alpha Emitters, by Country USD Million (2017-2022)
  • Table 55. Europe Alpha Emitters, by Application USD Million (2017-2022)
  • Table 56. Europe Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 57. Europe Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 58. Germany Alpha Emitters, by Application USD Million (2017-2022)
  • Table 59. Germany Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 60. Germany Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 61. France Alpha Emitters, by Application USD Million (2017-2022)
  • Table 62. France Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 63. France Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 64. Italy Alpha Emitters, by Application USD Million (2017-2022)
  • Table 65. Italy Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 66. Italy Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 67. United Kingdom Alpha Emitters, by Application USD Million (2017-2022)
  • Table 68. United Kingdom Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 69. United Kingdom Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 70. Netherlands Alpha Emitters, by Application USD Million (2017-2022)
  • Table 71. Netherlands Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 72. Netherlands Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 73. Rest of Europe Alpha Emitters, by Application USD Million (2017-2022)
  • Table 74. Rest of Europe Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 75. Rest of Europe Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 76. MEA Alpha Emitters, by Country USD Million (2017-2022)
  • Table 77. MEA Alpha Emitters, by Application USD Million (2017-2022)
  • Table 78. MEA Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 79. MEA Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 80. Middle East Alpha Emitters, by Application USD Million (2017-2022)
  • Table 81. Middle East Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 82. Middle East Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 83. Africa Alpha Emitters, by Application USD Million (2017-2022)
  • Table 84. Africa Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 85. Africa Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 86. North America Alpha Emitters, by Country USD Million (2017-2022)
  • Table 87. North America Alpha Emitters, by Application USD Million (2017-2022)
  • Table 88. North America Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 89. North America Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 90. United States Alpha Emitters, by Application USD Million (2017-2022)
  • Table 91. United States Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 92. United States Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 93. Canada Alpha Emitters, by Application USD Million (2017-2022)
  • Table 94. Canada Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 95. Canada Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 96. Mexico Alpha Emitters, by Application USD Million (2017-2022)
  • Table 97. Mexico Alpha Emitters, by Radionuclide Type USD Million (2017-2022)
  • Table 98. Mexico Alpha Emitters, by End-User USD Million (2017-2022)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Alpha Emitters: by Application(USD Million)
  • Table 107. Alpha Emitters Pancreatic Cancer , by Region USD Million (2023-2028)
  • Table 108. Alpha Emitters Prostate Cancer , by Region USD Million (2023-2028)
  • Table 109. Alpha Emitters Ovarian Cancer , by Region USD Million (2023-2028)
  • Table 110. Alpha Emitters Other , by Region USD Million (2023-2028)
  • Table 111. Alpha Emitters: by Radionuclide Type(USD Million)
  • Table 112. Alpha Emitters Fermium , by Region USD Million (2023-2028)
  • Table 113. Alpha Emitters Astatine , by Region USD Million (2023-2028)
  • Table 114. Alpha Emitters Curium , by Region USD Million (2023-2028)
  • Table 115. Alpha Emitters Radium , by Region USD Million (2023-2028)
  • Table 116. Alpha Emitters Actinium , by Region USD Million (2023-2028)
  • Table 117. Alpha Emitters Radon , by Region USD Million (2023-2028)
  • Table 118. Alpha Emitters Bismuth , by Region USD Million (2023-2028)
  • Table 119. Alpha Emitters Other , by Region USD Million (2023-2028)
  • Table 120. Alpha Emitters: by End-User(USD Million)
  • Table 121. Alpha Emitters Hospitals , by Region USD Million (2023-2028)
  • Table 122. Alpha Emitters Medical Research Institutions , by Region USD Million (2023-2028)
  • Table 123. Alpha Emitters Others , by Region USD Million (2023-2028)
  • Table 124. South America Alpha Emitters, by Country USD Million (2023-2028)
  • Table 125. South America Alpha Emitters, by Application USD Million (2023-2028)
  • Table 126. South America Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 127. South America Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 128. Brazil Alpha Emitters, by Application USD Million (2023-2028)
  • Table 129. Brazil Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 130. Brazil Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 131. Argentina Alpha Emitters, by Application USD Million (2023-2028)
  • Table 132. Argentina Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 133. Argentina Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 134. Rest of South America Alpha Emitters, by Application USD Million (2023-2028)
  • Table 135. Rest of South America Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 136. Rest of South America Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 137. Asia Pacific Alpha Emitters, by Country USD Million (2023-2028)
  • Table 138. Asia Pacific Alpha Emitters, by Application USD Million (2023-2028)
  • Table 139. Asia Pacific Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 140. Asia Pacific Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 141. China Alpha Emitters, by Application USD Million (2023-2028)
  • Table 142. China Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 143. China Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 144. Japan Alpha Emitters, by Application USD Million (2023-2028)
  • Table 145. Japan Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 146. Japan Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 147. India Alpha Emitters, by Application USD Million (2023-2028)
  • Table 148. India Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 149. India Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 150. South Korea Alpha Emitters, by Application USD Million (2023-2028)
  • Table 151. South Korea Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 152. South Korea Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 153. Australia Alpha Emitters, by Application USD Million (2023-2028)
  • Table 154. Australia Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 155. Australia Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 156. Rest of Asia-Pacific Alpha Emitters, by Application USD Million (2023-2028)
  • Table 157. Rest of Asia-Pacific Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 158. Rest of Asia-Pacific Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 159. Europe Alpha Emitters, by Country USD Million (2023-2028)
  • Table 160. Europe Alpha Emitters, by Application USD Million (2023-2028)
  • Table 161. Europe Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 162. Europe Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 163. Germany Alpha Emitters, by Application USD Million (2023-2028)
  • Table 164. Germany Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 165. Germany Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 166. France Alpha Emitters, by Application USD Million (2023-2028)
  • Table 167. France Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 168. France Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 169. Italy Alpha Emitters, by Application USD Million (2023-2028)
  • Table 170. Italy Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 171. Italy Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 172. United Kingdom Alpha Emitters, by Application USD Million (2023-2028)
  • Table 173. United Kingdom Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 174. United Kingdom Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 175. Netherlands Alpha Emitters, by Application USD Million (2023-2028)
  • Table 176. Netherlands Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 177. Netherlands Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 178. Rest of Europe Alpha Emitters, by Application USD Million (2023-2028)
  • Table 179. Rest of Europe Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 180. Rest of Europe Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 181. MEA Alpha Emitters, by Country USD Million (2023-2028)
  • Table 182. MEA Alpha Emitters, by Application USD Million (2023-2028)
  • Table 183. MEA Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 184. MEA Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 185. Middle East Alpha Emitters, by Application USD Million (2023-2028)
  • Table 186. Middle East Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 187. Middle East Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 188. Africa Alpha Emitters, by Application USD Million (2023-2028)
  • Table 189. Africa Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 190. Africa Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 191. North America Alpha Emitters, by Country USD Million (2023-2028)
  • Table 192. North America Alpha Emitters, by Application USD Million (2023-2028)
  • Table 193. North America Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 194. North America Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 195. United States Alpha Emitters, by Application USD Million (2023-2028)
  • Table 196. United States Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 197. United States Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 198. Canada Alpha Emitters, by Application USD Million (2023-2028)
  • Table 199. Canada Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 200. Canada Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 201. Mexico Alpha Emitters, by Application USD Million (2023-2028)
  • Table 202. Mexico Alpha Emitters, by Radionuclide Type USD Million (2023-2028)
  • Table 203. Mexico Alpha Emitters, by End-User USD Million (2023-2028)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Alpha Emitters: by Application USD Million (2017-2022)
  • Figure 5. Global Alpha Emitters: by Radionuclide Type USD Million (2017-2022)
  • Figure 6. Global Alpha Emitters: by End-User USD Million (2017-2022)
  • Figure 7. South America Alpha Emitters Share (%), by Country
  • Figure 8. Asia Pacific Alpha Emitters Share (%), by Country
  • Figure 9. Europe Alpha Emitters Share (%), by Country
  • Figure 10. MEA Alpha Emitters Share (%), by Country
  • Figure 11. North America Alpha Emitters Share (%), by Country
  • Figure 12. Global Alpha Emitters share by Players 2022 (%)
  • Figure 13. Global Alpha Emitters share by Players (Top 3) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 16. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 17. IBA Radiopharma Solution (Belgium) Revenue, Net Income and Gross profit
  • Figure 18. IBA Radiopharma Solution (Belgium) Revenue: by Geography 2022
  • Figure 19. Alpha Tau Medical Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 20. Alpha Tau Medical Ltd (Israel) Revenue: by Geography 2022
  • Figure 21. Actinium Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Actinium Pharmaceutical Inc. (United States) Revenue: by Geography 2022
  • Figure 23. RadioMedix Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. RadioMedix Inc. (United States) Revenue: by Geography 2022
  • Figure 25. Fusion Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Fusion Pharmaceuticals (Canada) Revenue: by Geography 2022
  • Figure 27. Telix Pharmaceuticals (Australia) Revenue, Net Income and Gross profit
  • Figure 28. Telix Pharmaceuticals (Australia) Revenue: by Geography 2022
  • Figure 29. Global Alpha Emitters: by Application USD Million (2023-2028)
  • Figure 30. Global Alpha Emitters: by Radionuclide Type USD Million (2023-2028)
  • Figure 31. Global Alpha Emitters: by End-User USD Million (2023-2028)
  • Figure 32. South America Alpha Emitters Share (%), by Country
  • Figure 33. Asia Pacific Alpha Emitters Share (%), by Country
  • Figure 34. Europe Alpha Emitters Share (%), by Country
  • Figure 35. MEA Alpha Emitters Share (%), by Country
  • Figure 36. North America Alpha Emitters Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • IBA Radiopharma Solution (Belgium)
  • Alpha Tau Medical Ltd (Israel)
  • Actinium Pharmaceutical Inc. (United States)
  • RadioMedix Inc. (United States)
  • Fusion Pharmaceuticals (Canada)
  • Telix Pharmaceuticals (Australia)
Select User Access Type

Key Highlights of Report


May 2023 248 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Alpha Emitters Market Quantitative research analysis
Global Alpha Emitters Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Alpha Emitters Market are by end use application [Pancreatic Cancer, Prostate Cancer, Ovarian Cancer and Other].
The Alpha Emitters Market is gaining popularity and expected to see strong valuation by 2028.
  • Increasing Incidence and Disorder of Target Conditions
  • Innovating Advanced Technology in the Market

Know More About Global Alpha Emitters Market Report?

Have a Query? Click Here

Other Related Reports

Emerging Mental Health Device and Platform Comprehensive Study by Type (Platforms, Devices), Application (Stress, Anxiety, Depression, Bipolar Disorder, Schizophrenia, Others), Therapy (Cognitive Beh...
$ 3800
Shoulder Implants- Comprehensive Study by Implant Type (Anatomical Shoulder Prosthesis, Reverse Shoulder Prosthesis), End-user (Hospitals, Ambulatory Surgical Center, Orthopaedic Clinics) Players an...
$ 3400
Fecal Management System Comprehensive Study by Patient Type (Adult, Pediatric), Product (Colostomy Bags, Irrigation System, Nerve Modulation Devices, Accessories), End-User (Home Care, Hospitals, Am...
$ 3800
Trench Fever Medicine Comprehensive Study by Type (Doxycycline, Tetracycline, Chloramphenicol, Others), Distribution Channel (Online, Offline), End-User (Hospital, Clinics, Ambulatory Surgical Center...
$ 3500
Medical Facility Disinfection System Comprehensive Study by Type (Steam Sterilizer, Ethylene Oxide Sterilizer, Others), Application (Hospitals and Clinics, Pharmaceutical, Others), Distribution Chann...
$ 3800
Connected Medical Technology - Comprehensive Study by Type (In Vitro Diagnostic (IVD) Devices, Cardiology Devices, Diagnostic Imaging Devices, Orthopedic Devices, Ophthalmology Devices, Others), Appl...
$ 3800